MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets

c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression. Although MYC is overexpressed in both early and metastatic disease and associated with poor survival, its impact on prostate transcriptional reprogramming remains elusive. We demonstrate that MYC overexpression significa...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Xintao, Boufaied, Nadia, Hallal, Tarek, Feit, Avery, de Polo, Anna, Luoma, Adrienne M., Alahmadi, Walaa, Larocque, Janie, Zadra, Giorgia, Xie, Yingtian, Gu, Shengqing, Tang, Qin, Zhang, Yi, Syamala, Sudeepa, Seo, Ji-Heui, Bell, Connor, O’Connor, Edward, Liu, Yang, Schaeffer, Edward M., Jeffrey Karnes, R., Weinmann, Sheila, Davicioni, Elai, Morrissey, Colm, Cejas, Paloma, Ellis, Leigh, Loda, Massimo, Wucherpfennig, Kai W., Pomerantz, Mark M., Spratt, Daniel E., Corey, Eva, Freedman, Matthew L., Shirley Liu, X., Brown, Myles, Long, Henry W., Labbé, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106722/
https://www.ncbi.nlm.nih.gov/pubmed/35562350
http://dx.doi.org/10.1038/s41467-022-30257-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106722/
https://www.ncbi.nlm.nih.gov/pubmed/35562350
http://dx.doi.org/10.1038/s41467-022-30257-z

Ejemplares similares